Which Pharmaceutical Companies Pay Doctors the Most?

The Scale of Industry Spending

Under the Sunshine Act, 1,925 companies reported payments to physicians in PY2024. The total: $13.9B. But the distribution is radically uneven. A handful of large pharmaceutical and device manufacturers account for billions, while thousands of smaller companies report less than $100,000 each.

This concentration mirrors the pharmaceutical industry itself. Companies with multi-billion-dollar revenue from specialty drugs invest heavily in physician engagement, clinical research, speaker programs, advisory boards, and consulting arrangements. These activities are legal and, in many cases, essential to advancing medical science. But the sheer scale of spending raises legitimate questions about independence and objectivity in healthcare.

Browse the full company rankings on the companies page to see every reporting entity and their total payments.

What Drives High Spending

Several factors explain why some companies report vastly higher payments than others:

• Product portfolio size: Companies with dozens of marketed drugs maintain larger networks of speakers, consultants, and advisory board members across multiple therapeutic areas. Each product may have its own promotional budget.
• Therapeutic complexity: Oncology drugs, biologics, and implantable devices require more physician education than simple oral medications. Companies in these spaces spend more per physician on training, speaking events, and clinical support.
• Clinical trial pipelines: Companies with active phase II and III trials pay physician investigators for patient recruitment, data collection, and protocol oversight. A single large trial can involve thousands of investigators across hundreds of sites, generating hundreds of millions in reported research payments.
• Competitive intensity: When multiple companies sell drugs for the same condition (e.g., rheumatoid arthritis, diabetes), promotional spending increases as each company invests in key opinion leader relationships and speaker programs to differentiate its product.
• Device companies vs. drug companies: Medical device manufacturers often report high per-physician spending because surgeons need hands-on training for each new device. A single orthopedic implant training may cost tens of thousands of dollars per physician.

General Payments vs. Research Payments

CMS categorizes all reported payments into two broad groups, and the distinction matters enormously for interpretation:

A company whose CMS filings lean toward research payments presents a fundamentally different picture than one leaning toward general payments. PlainPharmaWatch breaks down each company's General Payments by category so you can evaluate the nature, not just the magnitude, of that portion of their physician relationships.

Geographic Patterns in Spending

Industry spending is not evenly distributed across the country. States with major academic medical centers, large physician populations, and concentrations of pharmaceutical company headquarters consistently receive more. In the current dataset, California, Florida, Pennsylvania, Massachusetts, and Texas make up the top five states by total payments received. On a per-physician basis, states with smaller physician workforces but significant research institutions can rank disproportionately high.

Explore the state-level data to see how industry spending flows to physicians in each state.

How to Read a Spending Profile

Total payments

The headline number, every dollar transferred during the program year, summed across all categories. Useful for ranking but uninformative on its own. A $$500M total tells you scale; it does not tell you whether that money was research grants, speaker fees, or trial funding.

Number of physicians paid

Two companies can spend $$300M in a year and look identical until you check who they paid. Company A might have spread the money across 50,000 physicians at $$6,000 average; company B might have concentrated it among 200 physicians at $$1.5M average. The mean tells a very different story about the type of relationship.

General-vs-research payment mix

CMS reports Research payments through a separate track from the General Payments totals shown on PlainPharmaWatch company pages. A company whose CMS filings lean research-heavy (active clinical-trial pipelines) presents a different picture than one leaning toward general/promotional payments (consulting, speaking, meals); neither pattern is automatically problematic, but they are qualitatively different. PlainPharmaWatch's company pages show General Payments totals and category mix; comparing the research side requires cross-referencing CMS's own Research Payments data at openpaymentsdata.cms.gov.

Top recipient concentration

Look at how much of the company's total flows to its top 1%, 5%, and 10% of recipients. If 5% of physicians receive 60% of dollars, that is a key-opinion-leader (KOL) strategy. If the curve is flatter, top 5% gets 25% of dollars, that is broader engagement, often associated with field-based education programs.

Worked example: comparing two similarly-sized companies

Two hypothetical companies with the same total CMS-reported figure can have very different relationship patterns, one might lean toward research payments (a typical profile for an oncology biotech running phase-III trials), while another leans toward general payments split between speaker fees, meals, and travel. Same headline number, fundamentally different relationship pattern. PlainPharmaWatch's compare tool shows each company's real General Payments category mix side by side.

"Total spend is a starting line, not a finish line. The story is in the mix, research vs. general, broad vs. concentrated, episodic vs. recurring."

What the Data Does and Doesn't Tell You

High spending by a company does not automatically indicate improper conduct. Many of the largest-spending companies are also the world's leading investors in pharmaceutical research. However, the data provides the transparency needed for informed analysis:

• What it tells you: How much each company spends, where the money goes, what types of payments dominate, and how many physicians receive payments.
• What it doesn't: Whether the spending was appropriate, whether it influenced prescribing decisions, or whether the clinical outcomes justified the investment. Those questions require additional context beyond what any dataset can provide.

Frequently Asked Questions